News

Investor Toolkit

Webcast ImageWebcast
Emergent BioSolutions Inc. at Bank of America Merrill Lynch Health Care Conference (Replay)
05/16/13 at 10:40 a.m. PT
Keyword Search
 
2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
05/16/13Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 23, 2013 at 9:00 AM Eastern; Webcast Will Be Available Printer Friendly Version
05/09/13Emergent BioSolutions to Webcast Presentation at Bank of America Merrill Lynch 2013 Health Care Conference Printer Friendly Version
05/03/13Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer Printer Friendly Version
05/02/13Emergent BioSolutions Reports Financial Results for First Quarter 2013Download PDFPrinter Friendly Version
04/30/13Emergent BioSolutions Participates in NATO Defense against Terrorism Workshop at the Counter Terror Expo in London Printer Friendly Version
04/29/13Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody Day Printer Friendly Version
04/25/13Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc.Download PDFPrinter Friendly Version
04/11/13Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune DiseasesDownload PDFPrinter Friendly Version
04/11/13Emergent BioSolutions Announces Positive Preclinical Efficacy and PK Data for Its New Bispecific Adaptir Protein Therapeutic ES414 at AACRDownload PDFPrinter Friendly Version
04/05/13Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical DataDownload PDFPrinter Friendly Version
04/04/13Emergent BioSolutions to Release First Quarter 2013 Financial Results and Conduct a Conference Call on May 2, 2013Download PDFPrinter Friendly Version
03/07/13Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2012Download PDFPrinter Friendly Version
02/11/13Emergent BioSolutions to Present at Cowen and Company 33rd Annual Health Care ConferenceDownload PDFPrinter Friendly Version
02/04/13Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet Printer Friendly Version
02/01/13Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013Download PDFPrinter Friendly Version
01/22/13Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThraxDownload PDFPrinter Friendly Version
01/17/13Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThraxDownload PDFPrinter Friendly Version
01/07/13Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013Download PDFPrinter Friendly Version
01/02/13Emergent’s TRU-016 for CLL Receives Orphan Medicinal Product Designation from European CommissionDownload PDFPrinter Friendly Version

© 2012 Emergent BioSolutions Inc. All rights reserved. ABOUT | PRODUCT | PIPELINE | PARTNERING | INVESTORS | CAREERS | NEWSROOM | CONTACT US | TERMS OF USE | PRIVACY POLICY